Spots Global Cancer Trial Database for A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Official Title: A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Study ID: NCT01877005
Conditions
Interventions
Study Description
Brief Summary: Phase II study to assess the efficacy of 6 cycles of oral JAK1/2 inhibitor ruxolitinib in patients with advanced Hodgkin's lymphoma for whom no curative option is available.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCL Louvain St Luc, Brussels, , Belgium
Université Catholique de Louvain Mont Godinne, Yvoir, , Belgium
Chu Cote de Nacre, Caen, , France
Hopital Henri Mondor, Creteil, , France
Chu Dijon, Dijon, , France
Chru de Lille, Lille, , France
Centre Leon Berard, Lyon, , France
Centre Hospitalier Lyon Sud, Lyon, , France
CHU de Nantes, Hotel Dieu, Nantes, , France
Centre Henri Becquerel, Rouen, , France
Contact Details
Name: Eric Van Den Neste, MD
Affiliation: Lymphoma Study Association
Role: PRINCIPAL_INVESTIGATOR
Name: Franck Morschhauser, MD
Affiliation: Lymphoma Study Association
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
